Metformin in the Era of New Antidiabetics

Abstract

Type II diabetes mellitus is a known cardiovascular risk factor and its prevalence continues to increase. A revolution in the Type II diabetes mellitus treatment has occurred with the arrival of new antidiabetic drugs, which are thought to compromise metformin place. We aim to review the pharmacology, available evidence and clinical aspects of metformin use in the era of new antidiabetics.

Keywords:

• antidiabetic drug
• cardiovascular outcome
• GLP1 receptor agonist
• metformin
• SGLT2 inhibitors
• Type 2 diabetes mellitus

Acknowledgments

The authors acknowledge CG Sebastián for manuscript review and editorial assistance.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.